Commercial Novo’s CEO champions “record-breaking start” for Wegovy pill in US market Pharmaceutical TechnologyNovo Nordisk's Wegovy pill is already providing financial fuel in the company's bid to catch Eli Lilly.Metabolic & GLP-1Read full story pharminent May 8, 2026 (Last updated: May 10, 2026) Pharmaceutical Technology Novo Nordisk’s Wegovy pill is already providing financial fuel in the company’s bid to catch Eli Lilly. Metabolic & GLP-1 Read full story Post navigation Previous: Angelini inks $4.1B Catalyst buy to enter US rare disease marketNext: Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026